Warner Chilcott Company Inc. and Foamix Ltd. has announced that the two companies have signed an agreement to jointly develop gynaecologic foam.

Under the terms of this agreement, Foamix will be responsible for developing the foam formulations and Warner Chilcott will have an option to continue definitive development and worldwide commercialisation of the product. Additional terms were not disclosed.

"We believe that Foamix foam offers an appealing way to deliver treatment to patients vaginally" said Roger Boissonneault, CEO and president of Warner Chilcott.

"We are very proud to expand our partnership with an industry leader such as Warner Chilcott", said Foamix CEO Dr Dov Tamarkin. "Foam offers properties that increase usability, encourage compliance and boost user satisfaction. Foamix foams are alcohol-free and able to effectively deliver a broad range of actives. Our foams are non-drip, with easy application, thus making them uniquely suitable for gynaecologic application."

"We believe that Foamix foam offers an appealing way to deliver treatment to patients with acne" said Roger Boissonneault, CEO and president of Warner Chilcott.

Warner Chilcott is a specialty pharmaceutical company focused on developing, manufacturing, marketing and selling branded prescription pharmaceutical products in women's healthcare and dermatology in the US. WCRX-G.